Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 929016-96-6 Chemical Structure| 929016-96-6

Structure of Pracinostat
CAS No.: 929016-96-6

Chemical Structure| 929016-96-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pracinostat is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6 and has no activity against the class III isoenzyme SIRT I.

Synonyms: SB939

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pracinostat

CAS No. :929016-96-6
Formula : C20H30N4O2
M.W : 358.48
SMILES Code : O=C(NO)/C=C/C1=CC=C2C(N=C(CCCC)N2CCN(CC)CC)=C1
Synonyms :
SB939
MDL No. :MFCD17215206
InChI Key :JHDKZFFAIZKUCU-ZRDIBKRKSA-N
Pubchem ID :49855250

Safety of Pracinostat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Related Pathways of Pracinostat

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC8

    HDAC8, IC50:140 nM

  • HDAC10

    HDAC10, IC50:40 nM

  • HDAC3

    HDAC3, IC50:43 nM

  • HDAC4

    HDAC4, IC50:56 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
FaDu cells 0.2 µM 15 days Suppressed 3D spheroid growth of FaDu cells, significantly reducing spheroid volume when combined with X-ray irradiation PMC11640432
LU505 cells 125nM 21 days Pracinostat treatment resulted in increased E-CADHERIN expression and global H3K27Ac levels. PMC6294438
32D murine myeloid cells 125-500 nM 24 hours Pracinostat treatment decreased both pJAK2 (Y1007/08) and pSTAT5 (Y694) levels, and also total JAK2 and STAT5 protein in JAK2V617F mutant cells. PMC3366067
HEL92.1.7 and SET-2 cells 125-500 nM 24 hours Pracinostat treatment decreased both pJAK2 (Y1007/08) and pSTAT5 (Y694) levels, and also total JAK2 and STAT5 protein in JAK2V617F mutant cells. PMC3366067
MV4-11 and MOLM-13 cells 500 nM 24 hours Pracinostat treatment nearly completely ablated pFLT3 (Y591), accompanied by a decrease in total FLT3 and pSTAT5. PMC3366067
HCT116 1 μM 24 hours Pracinostat significantly induced mitochondrial fragmentation in CRC cells, as evidenced by the elevated number of fragmented mitochondria, the decrease in tubular mitochondria and the ratio of rod/branch length. PMC10657975
HT29 0–2 μM 24 hours Pracinostat increased the number of fragmented mitochondria. PMC10657975
HEK293 cells 1 µM 48 hours Confirming the effect of Pracinostat on BDNF mRNA expression, it was shown to significantly increase BDNF mRNA levels PMC6429164
DLBCL cells 250 nM 6 hours or 72 hours To evaluate the antiproliferative activity of Pracinostat on DLBCL cells, the results showed that Pracinostat exhibited robust activity across all lymphoma histotypes. PMC8152508
FaDu cells 1 µM 7-14 days Enhanced radiosensitivity of FaDu cells, significantly inhibiting clonogenic survival PMC11640432
A253 cells 1 µM 7-14 days Enhanced radiosensitivity of A253 cells, significantly inhibiting clonogenic survival PMC11640432
UMSCC11b cells 1 µM 7-14 days Enhanced radiosensitivity of UMSCC11b cells, significantly inhibiting clonogenic survival PMC11640432
NCI-H1299 500 nM 72 hours To evaluate the effect of Pracinostat on NCI-H1299 cells, results showed that Pracinostat induced transcription of non-annotated transcription start sites (TINATs). PMC6005702
BCR-DLBCL and OxPhos-DLBCL cells 250 nM 72 hours To evaluate the apoptosis induction effect of Pracinostat on BCR-DLBCL and OxPhos-DLBCL cells, the results showed marked apoptosis induction in BCR-DLBCLs, while the percentage of apoptotic cells in OxPhos-DLBCLs was lower. PMC8152508
AML cells 100 nM 96 hours To evaluate the effect of Pracinostat on the growth of AML cells, results showed that Pracinostat inhibited the growth of AML cells PMC8941473
Human Neural Progenitor Cells (HNPCs) 1 µM Screening for small compounds capable of modulating BDNF expression, Pracinostat was found to have a significant impact on BDNF expression PMC6429164

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice AML model 50 nM Not specified To evaluate the effect of Pracinostat on AML model mice, results showed that Pracinostat significantly suppressed the growth of AML cells PMC8941473
Mice Neuroblastoma xenograft model Intraperitoneal injection 150 mg/kg Once daily for 5 days To evaluate the effect of Pracinostat on the neuroblastoma xenograft model, results showed that Pracinostat significantly increased transcription of LTR12C. PMC6005702
Mice Rb1/Trp53/Crebbp-deficient SCLC model Oral 100mg/kg Daily, 5 days per week for 3 weeks To evaluate the efficacy of Pracinostat in the Rb1/Trp53/Crebbp-deficient SCLC model, it was found that Pracinostat treatment significantly inhibited tumor growth, with some mice showing complete regression. PMC6294438
BALB/c nude mice MV4-11 xenograft model Oral 25 or 50 mg/kg Daily for 21 days Pracinostat significantly inhibited tumor growth (TGI), by 59% and 116%, respectively. Complete tumor regression was observed in 6 out of 10 animals at the end of the treatment after the 50-mg dose. PMC3366067
BalB/c Nude mice A549 xenograft model Intraperitoneal injection 20 mg/kg Once daily for 21 days To evaluate the antitumor efficacy of 3b in the A549 xenograft model, showing significant inhibition of tumor growth with negligible effect on mean body weight. PMC10930102
NOD-SCID mice DLBCL xenograft model Oral gavage 100 mg/kg Once daily, 5 days per week for 11 days To evaluate the antilymphoma activity of Pracinostat in the DLBCL xenograft model, the results showed that Pracinostat significantly delayed tumor growth in the TMD8 model and remained effective throughout the experiment. PMC8152508
Nude mice CRC xenograft model Oral 25 mg/kg Every two days Pracinostat significantly suppressed the growth of CRC tumors with high CDK5 expression. PMC10657975

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01184274 Leukemia|Solid Tumours PHASE1 COMPLETED 2014-01-16 Alberta Children's Hospital, C... More >>algary, Alberta, T3B 6A8, Canada|Stollery Children's Hospital, Edmonton, Alberta, T6G 2B7, Canada|Children's and Women's Health Centre of BC Branch, Vancouver, British Columbia, V6H 3V4, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, B3K 6R8, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada|CHU Sainte-Justine, Montreal, Quebec, H3T 1C5, Canada Less <<
NCT01112384 Metastatic Sarcoma PHASE2 COMPLETED 2014-01-16 Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Program, London, Ontario, N6A 4L6, Canada|Ottawa Health Research Institute - General Division, Ottawa, Ontario, K1H 8L6, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|McGill University - Dept. Oncology, Montreal, Quebec, H2W 1S6, Canada Less <<
NCT01200498 Myeloproliferative Disorders PHASE2 COMPLETED 2025-11-12 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.95mL

2.79mL

1.39mL

27.90mL

5.58mL

2.79mL

References

 

Historical Records

Categories